ALT CHANGES AND ADVERSE EVENTS OF TELBIVUDINE IN HEPATITIS-B PATIENTS-AN EXPERIENCE OF 11 PATIENTS

Hepatitis-b virus (hbv) infection is a major global health problem. of the two billion people who have been infected,more than 350 million have chronic hepatitis. it is estimated that 235,000-328,000 people die annually due to liver cirrhosis and hepatocellular carcinoma,we assessed the short term outcomes of treatment with telbivudine in 11 adults aged 14-41 years with hbeag-positive or hbeag-negative chronic hepatitis-b (chb). treatment of chronic hepatitis-b patients with telbivudine shows 43.1% reduction in serum alt with no significant adverse effects.